Annexon, Inc. (ANNX)
NASDAQ: ANNX · Real-Time Price · USD
3.370
+0.580 (20.79%)
At close: Sep 26, 2025, 4:00 PM EDT
3.399
+0.029 (0.86%)
After-hours: Sep 26, 2025, 7:59 PM EDT
Annexon Employees
Annexon had 100 employees as of December 31, 2024. The number of employees increased by 29 or 40.85% compared to the previous year.
Employees
100
Change (1Y)
29
Growth (1Y)
40.85%
Revenue / Employee
n/a
Profits / Employee
-$1,887,830
Market Cap
370.32M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ANNX News
- 20 days ago - Annexon, Inc. (ANNX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha
- 22 days ago - Annexon, Inc. (ANNX) Presents at Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - Annexon Biosciences to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 5 weeks ago - Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - GlobeNewsWire
- 7 weeks ago - Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy - GlobeNewsWire
- 2 months ago - Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy - GlobeNewsWire
- 2 months ago - Annexon: Lead GBS Therapy Stokes Near-Term Potential - Seeking Alpha